Trial & Business Updates: 11/1/2000

Printer Friendly Version

Priority Lists

Disease Committee	Last Changed
Breast Cancer	11/1/23
Cancer Care Delivery	9/1/22
Cancer Survivorship	1/14/19
comboMATCH	12/1/23
Early Therapeutics & Rare Cancers	12/1/23
Gastrointestinal Cancer	12/1/23
Genitourinary Cancer	12/1/23
Head and Neck Cancer	12/15/07
iMATCH	11/1/22
Immunomolecular Therapeutics	6/15/20
Leukemia	3/22/23
Lung Cancer	12/1/23
LungMAP	12/15/23
Lymphoma	1/17/24
Melanoma	4/18/22
Myeloma	4/1/24
Other	2/1/14
Prevention & Epidemiology	7/1/24
Symptom Control and Quality of Life	4/1/23

Protocol Posting of 11/1/2000

Activations
Closures
Amendments, Revisions, Memoranda
Other New Items

Activations

S0007Phase II

Evaluation of 3 Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Study Coordinator(s)	Maha H.A. Hussain, M.D., Wolfram E. Samlowski, M.D.
Participants	Members, NCORP, Medical Oncologists

Closures

Amendments, Revisions, Memoranda

Other New Items

IP - Pts Must Be Informed
AC - Consent Must Be Amended
CBR - No Registration Allowed until IRB Review
RC - Formal Re-consent Required
FBR - Full Board Review Required
ER - Expedited Review Acceptable
NR - No IRB Review Required